Format
Sort by
    Items per page

    Send to

    Choose Destination

    Links from PubMed

    Items: 1 to 20 of 152

    1.

    Frequency and epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates susceptible to third-generation cephalosporins or to aztreonam.

    Bert F, Bialek-Davenet S, Leflon-Guibout V, Noussair L, Nicolas-Chanoine MH.

    Med Mal Infect. 2014 Feb;44(2):76-8. doi: 10.1016/j.medmal.2013.12.004. Epub 2014 Feb 10.

    PMID:
    24525113
    2.

    Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.

    Jean SS, Lee WS, Bai KJ, Lam C, Hsu CW, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Chen RJ, Hsueh PR.

    J Microbiol Immunol Infect. 2015 Feb;48(1):85-91. doi: 10.1016/j.jmii.2013.07.002. Epub 2013 Aug 22.

    3.

    Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.

    Wang P, Hu F, Xiong Z, Ye X, Zhu D, Wang YF, Wang M.

    J Clin Microbiol. 2011 Sep;49(9):3127-31. doi: 10.1128/JCM.00222-11. Epub 2011 Jul 13.

    4.

    Occurrence of extended-spectrum beta-lactamases in Enterobacteriaceae isolated from hospitalized patients in Curitiba, southern Brazil.

    Nogueira Kda S, Higuti IH, do Nascimento AJ, Terasawa LB, de Oliveira S, Matos AP, de Souza HA, Cogo LL, Dalla Costa LM.

    Braz J Infect Dis. 2006 Dec;10(6):390-5.

    5.
    6.

    Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.

    McWilliams CS, Condon S, Schwartz RM, Ginocchio CC.

    J Clin Microbiol. 2014 Jul;52(7):2653-5. doi: 10.1128/JCM.03613-13. Epub 2014 Apr 30.

    7.

    Antimicrobial susceptibility testing for Klebsiella pneumoniae isolates resistant to extended-spectrum beta-lactam antibiotics.

    Jan IS, Hsueh PR, Teng LJ, Ho SW, Luh KT.

    J Formos Med Assoc. 1998 Oct;97(10):661-6.

    PMID:
    9830274
    8.

    Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.

    Kohner PC, Robberts FJ, Cockerill FR 3rd, Patel R.

    J Clin Microbiol. 2009 Aug;47(8):2419-25. doi: 10.1128/JCM.00508-09. Epub 2009 Jun 3.

    9.

    In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam.

    Cheng NC, Liu CY, Huang YT, Liao CH, Teng LJ, Hsueh PR.

    J Antimicrob Chemother. 2012 Jun;67(6):1413-21. doi: 10.1093/jac/dks042. Epub 2012 Feb 17.

    PMID:
    22345386
    10.

    Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals.

    Zemelman C, Bello H, Domínguez M, González G, Mella S, Zemelman R.

    Diagn Microbiol Infect Dis. 2001 May-Jun;40(1-2):41-3.

    PMID:
    11448562
    11.
    12.

    [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].

    Susić E.

    Acta Med Croatica. 2004;58(4):307-12. Croatian.

    PMID:
    15700687
    13.

    Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.

    Nijssen S, Florijn A, Bonten MJ, Schmitz FJ, Verhoef J, Fluit AC.

    Int J Antimicrob Agents. 2004 Dec;24(6):585-91.

    PMID:
    15555882
    14.

    Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.

    Huang CC, Chen YS, Toh HS, Lee YL, Liu YM, Ho CM, Lu PL, Liu CE, Chen YH, Wang JH, Tang HJ, Yu KW, Liu YC, Chuang YC, Xu Y, Ni Y, Ko WC, Hsueh PR.

    Int J Antimicrob Agents. 2012 Jun;40 Suppl:S4-10. doi: 10.1016/S0924-8579(12)70003-1.

    PMID:
    22749058
    16.

    In-vitro activity of FCE 22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation cephalosporins.

    Jarlier V, Nicolas MH, Philippon A, Giroir AM, Grosset J.

    J Antimicrob Chemother. 1989 Aug;24(2):165-72.

    PMID:
    2676939
    17.

    Extended spectrum β-lactamase producers among nosocomial Enterobacteriaceae in Latin America.

    Guzmán-Blanco M, Labarca JA, Villegas MV, Gotuzzo E; Latin America Working Group on Bacterial Resistance..

    Braz J Infect Dis. 2014 Jul-Aug;18(4):421-33. doi: 10.1016/j.bjid.2013.10.005. Epub 2014 Jan 3. Review.

    18.

    Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.

    Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N.

    Antimicrob Agents Chemother. 2011 Jan;55(1):390-4. doi: 10.1128/AAC.00756-10. Epub 2010 Nov 1.

    19.

    In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

    Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ.

    Antimicrob Agents Chemother. 2009 Jun;53(6):2360-6. doi: 10.1128/AAC.01452-08. Epub 2009 Apr 6.

    20.

    Supplemental Content

    Support Center